SC
Stempoint Capital Portfolio holdings
AUM
$311M
This Quarter Return
+8.92%
1 Year Return
+15.22%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$311M
AUM Growth
+$311M
(-0.8%)
Cap. Flow
-$5.24M
Cap. Flow
% of AUM
-1.69%
Top 10 Holdings %
Top 10 Hldgs %
50.16%
Holding
74
New
18
Increased
16
Reduced
15
Closed
20
Top Buys
| 1 |
Cidara Therapeutics
CDTX
|
$13M |
| 2 |
Legend Biotech
LEGN
|
$9.59M |
| 3 |
Rhythm Pharmaceuticals
RYTM
|
$9.03M |
| 4 |
CNTA
Centessa Pharmaceuticals
CNTA
|
$8.83M |
| 5 |
Mineralys Therapeutics
MLYS
|
$8.55M |
Top Sells
| 1 |
Roivant Sciences
ROIV
|
$22.3M |
| 2 |
Revolution Medicines
RVMD
|
$11.3M |
| 3 |
Nuvalent
NUVL
|
$9.96M |
| 4 |
Xenon Pharmaceuticals
XENE
|
$9.21M |
| 5 |
CG Oncology
CGON
|
$7.1M |
Sector Composition
| 1 | Healthcare | 99.49% |
| 2 | Financials | 0.51% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Apogee Therapeutics
APGE
$2.17B
| $3.67M | 1.18% |
+84,466
| New | +$3.67M |
|
27
IDEAYA Biosciences
IDYA
$2.23B
| $3.49M | 1.12% |
165,885
+98,886
| +148% | +$2.08M |
|
28
Protara Therapeutics
TARA
$120M
| $3.47M | 1.11% |
1,143,677
-46,902
| -4% | -$142K |
|
|
BBOT
29
BridgeBio Oncology Therapeutics, Inc. Common Stock
BBOT
$708M
| $3.29M | 1.06% |
315,812
+114,912
| +57% | +$1.2M |
|
30
EyePoint Pharmaceuticals
EYPT
$797M
| $3.1M | 0.99% |
+329,254
| New | +$3.1M |
|
31
Arcutis Biotherapeutics
ARQT
$1.84B
| $2.88M | 0.93% |
205,672
-234,401
| -53% | -$3.29M |
|
32
Rezolute
RZLT
$619M
| $2.88M | 0.92% |
+644,654
| New | +$2.88M |
|
33
Taysha Gene Therapies
TSHA
$797M
| $2.78M | 0.89% |
+1,203,941
| New | +$2.78M |
|
34
NewAmsterdam Pharma
NAMS
$2.71B
| $2.76M | 0.89% |
152,652
+48,067
| +46% | +$870K |
|
35
Biohaven
BHVN
$1.68B
| $2.47M | 0.79% |
174,754
-75,810
| -30% | -$1.07M |
|
36
Regeneron Pharmaceuticals
REGN
$61.3B
| $2.45M | 0.79% |
+4,672
| New | +$2.45M |
|
37
BridgeBio Pharma
BBIO
$9.89B
| $2.36M | 0.76% |
54,630
-153,807
| -74% | -$6.64M |
|
38
Janux Therapeutics
JANX
$1.37B
| $2.08M | 0.67% |
89,933
-252,129
| -74% | -$5.82M |
|
39
Oric Pharmaceuticals
ORIC
$1.01B
| $2.04M | 0.65% |
+200,785
| New | +$2.04M |
|
|
MBX
40
MBX Biosciences, Inc. Common Stock
MBX
$507M
| $1.61M | 0.52% |
141,021
+44,406
| +46% | +$507K |
|
|
PCSC
41
Perceptive Capital Solutions Corp Class A Ordinary Shares
PCSC
$117M
| $1.59M | 0.51% |
150,000
| – | – |
|
42
Praxis Precision Medicines
PRAX
$958M
| $1.36M | 0.44% |
+32,255
| New | +$1.36M |
|
43
GH Research
GHRS
$837M
| $1.23M | 0.39% |
+100,826
| New | +$1.23M |
|
44
Tango Therapeutics
TNGX
$747M
| $1.07M | 0.34% |
+208,800
| New | +$1.07M |
|
45
Protagonist Therapeutics
PTGX
$3.67B
| $927K | 0.3% |
16,770
-32,471
| -66% | -$1.79M |
|
|
TECX
46
Tectonic Therapeutic, Inc. Common Stock
TECX
$312M
| $795K | 0.26% |
+40,000
| New | +$795K |
|
47
ADC Therapeutics
ADCT
$345M
| $759K | 0.24% |
+283,286
| New | +$759K |
|
|
VRNA
48
Verona Pharma
VRNA
$9.16B
| $701K | 0.22% |
+7,407
| New | +$701K |
|
|
ABVX
49
Abivax
ABVX
$6.2B
| $671K | 0.22% |
+87,748
| New | +$671K |
|
50
MindMed
MNMD
$676M
| $590K | 0.19% |
+90,852
| New | +$590K |
|